Literature DB >> 10930150

Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression.

H Hatano1, S Vogel, C Yoder, J A Metcalf, R Dewar, R T Davey, M A Polis.   

Abstract

OBJECTIVE: To evaluate the relationship between the HIV viral burden in individuals prior to receiving highly-active antiretroviral therapy (HAART) and the viral burden after withdrawal of HAART. DESIGN AND
SETTING: Retrospective cohort study at the National Institutes of Health, Bethesda, Maryland, USA. PATIENTS: Fourteen HIV-infected patients who achieved and maintained viral control on HAART who subsequently discontinued HAART. MAIN OUTCOME MEASURES: Pre- and post-HAART viral loads measured from plasma or serum.
RESULTS: Patients achieved viral control (< 500 copies/ml) on HAART in a median 28 days (range, 15-490 days; mean, 72 days), maintained viral control for a median 661 days (range, 53-1067 days; mean, 611 days), and subsequently discontinued HAART for a median 49 days (range, 14-196 days; mean, 73 days). The median difference between the pre- and post-HAART viral loads was 0.16 log10 (range, -0.72 to 1.05 log10; mean, 0.19 log10). The median absolute difference between the pre- and post-HAART viral loads was 0.43 log10 (range, 0.06-1.05 log10; mean, 0.46 log10). Nine individuals had post-HAART values higher than pre-HAART values, five had lower values. Median duration between pre- and post-HAART viral load measurements was 1757 days (range, 117-3177 days; mean, 1756 days), or 4.8 years.
CONCLUSIONS: After discontinuing HAART, individuals had rebounds in their viral burdens approximating pre-HAART levels, even after a significant lapse of time approaching 5 years. Our data suggest that an intrinsic viral load set-point may exist, and that a single interruption of an effective regimen with viral suppression for almost 2 years does not significantly alter this set-point.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10930150     DOI: 10.1097/00002030-200007070-00008

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  27 in total

1.  Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.

Authors:  T W Chun; J S Justement; S Moir; C W Hallahan; L A Ehler; S Liu; M McLaughlin; M Dybul; J M Mican; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

2.  Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.

Authors:  G M Ortiz; M Wellons; J Brancato; H T Vo; R L Zinn; D E Clarkson; K Van Loon; S Bonhoeffer; G D Miralles; D Montefiori; J A Bartlett; D F Nixon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

Review 3.  Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.

Authors:  Ume L Abbas; John W Mellors
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

4.  Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.

Authors:  Annette Oxenius; David A Price; Huldrych F Günthard; Sara J Dawson; Catherine Fagard; Luc Perrin; Marek Fischer; Rainer Weber; Montserrat Plana; Felipe García; Bernard Hirschel; Angela McLean; Rodney E Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

Review 5.  Immune-based therapies: an adjunct to antiretroviral treatment.

Authors:  Jeffrey M Jacobson
Journal:  Curr HIV/AIDS Rep       Date:  2005-06       Impact factor: 5.071

6.  Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461.

Authors:  James I Mullins; Laura Heath; James P Hughes; Jessica Kicha; Sheila Styrchak; Kim G Wong; Ushnal Rao; Alexis Hansen; Kevin S Harris; Jean-Pierre Laurent; Deyu Li; Jeffrey H Simpson; John M Essigmann; Lawrence A Loeb; Jeffrey Parkins
Journal:  PLoS One       Date:  2011-01-14       Impact factor: 3.240

7.  Short Communication: Cascade of Antiretroviral Therapy Adherence in Virologically Suppressed Persons Living with HIV.

Authors:  Jose R Castillo-Mancilla; Ryan P Coyle; Stacey S Coleman; Mary Morrow; Edward M Gardner; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Samantha MaWhinney; Peter L Anderson
Journal:  AIDS Res Hum Retroviruses       Date:  2019-07-30       Impact factor: 2.205

8.  Implications of Measurement Assay Type in Design of HIV Experiments.

Authors:  LaMont Cannon; Aditya Jagarapu; Cesar A Vargas-Garcia; Michael J Piovoso; Ryan Zurakowski
Journal:  Proc IEEE Conf Decis Control       Date:  2018-01-23

9.  Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in Canada.

Authors:  H Samji; T E Taha; D Moore; A N Burchell; A Cescon; C Cooper; J M Raboud; M B Klein; M R Loutfy; N Machouf; C M Tsoukas; J S G Montaner; R S Hogg
Journal:  HIV Med       Date:  2014-09-01       Impact factor: 3.180

10.  Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines.

Authors:  Sunil Kannanganat; Bill G Kapogiannis; Chris Ibegbu; Lakshmi Chennareddi; Paul Goepfert; Harriet L Robinson; Jeffrey Lennox; Rama Rao Amara
Journal:  J Virol       Date:  2007-08-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.